The goal of this agreement is to incorporate SINTX AP2 silicon nitride powder into polymer materials.
These materials will become safe and effective surfaces for IT devices such as cases for cell phones and tablets that are touched frequently.
SINTX and Iwatani aim to create surfaces that resist bacteria and viruses.
The development of these products may help prevent and reduce the spread of respiratory diseases like SARS-CoV-2, Influenza A, and H1N1 by inactivating viruses and bacteria on the polymer surfaces.
SINTX and Iwatani intend to capitalize on recent and promising data demonstrating the potential of SINTX AP2silicon nitride powder to inactivate the SARS-CoV-2 virus that is responsible for the global COVID-19 pandemic.
Studies showing the rapid inactivation of SARS-CoV-2 by SINTX's silicon nitride are the latest in a series of papers showing similar activity of silicon nitride against a variety of bacteria and viral strains, the companies said.
SINTX and Iwatani plan to jointly fund collaborative product development activities in Salt Lake City, Utah, and Japan with the support of external laboratories as well.
SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications.
The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners.
The company presently manufactures silicon nitride powders and components in its FDA registered, AS9100D certified, and ISO 13485:2016 certified manufacturing facility.
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Tissue Regenix secures CE and UKCA certifications for OrthoPure XT
Terumo Corporation expands stroke portfolio in EMEA with SOFIA Flow 88 catheter launch
Crossject advances ZENEO manufacturing with scalable aseptic filling module ahead of product rollout
ZYLOX Unicorn Vascular Closure Device approved in Indonesia
Mindray unveils BeneVision V Series at Euroanaesthesia 2025, advancing precision monitoring
Unicon Pharma and VRR Life Sciences partner support digital transformation in life sciences
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software